gutflix
GI learning, personalised

Summary

CLINICAL RESULTS OF 158 PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE TREATED BY A NOVEL IMPLANTABLE DEVICE: TWO-YEAR FOLLOW-UP

Thorsten Lehmann

UEG Week Vienna 2024 | Poster

Oesophagus

October 13, 2024

A German case series of 158 GERD patients treated with RefluxStop device showed 90.9% improvement in quality-of-life scores and 96.3% reduction in PPI use at 20-month follow-up.

KEY POINTS

- Median GERD-HRQL score improved from 22 at baseline to 2 at 20±7-month follow-up (p<. 001), representing a 90.9% improvement.
- PPI use decreased from 96.5% of patients at baseline to 3.6% at follow-up, a 96.3% reduction.
- All 18 cases of preoperative dysphagia resolved after surgery; new-onset dysphagia occurred in 3.2% of patients but did not require dilation.
- Hiatal hernia recurrence occurred in 1.3% and was managed with device repositioning; device penetration and migration occurred in 1.3% due to excessively tight suturing, with one patient requiring subsequent Toupet fundoplication.
- Authors conclude that RefluxStop shows promising clinical effectiveness as a novel GERD treatment but state that additional evaluation is necessary; authors disclose travel grants and speaking honoraria from the device manufacturer.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/730989ec-9112-11ef-8ee6-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.